Filing Details

Accession Number:
0001179110-21-010165
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-16 16:02:33
Reporting Period:
2021-11-12
Accepted Time:
2021-11-16 16:02:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
744218 Celldex Therapeutics Inc. CLDX In Vitro & In Vivo Diagnostic Substances (2835) 133191702
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1648010 C. Diane Young C/O Celldex Therapeutics, Inc.
53 Frontage Road, Suite 220
Hampton NJ 08827
Svp, Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-11-12 4,600 $10.38 6,715 No 4 M Direct
Common Stock Disposition 2021-11-12 4,600 $42.94 2,115 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option (Right to Buy) Disposition 2021-11-12 4,600 $0.00 4,600 $10.38
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
67,400 2030-06-18 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6400 to $43.2000 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  2. 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.